EUCTR2016-000588-17-FR进行中（未招募）1 期
A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426) - Pembrolizumab plus axitinib vs. sunitinib monotherapy in advanced/metastatic renal cell carcinoma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 840
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Be > or = 18 years of age on day of signing informed consent
- •- Have histologically confirmed diagnosis of RCC with clear cell component with or without sarcomatoid features
- •- Have locally advanced/metastatic disease (i.e., Stage IV RCC per American Joint Committee on Cancer) or have recurrent disease
- •- Have measurable disease per RECIST 1.1 as assessed by the investigator /site radiologist. Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
- •- Have received no prior systemic therapy for advanced RCC
- •- Provide tumor tissue for biomarker analysis
- •- Demonstrate adequate organ function
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 400
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 440
排除标准
- •- Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to randomization
- •- Has had major surgery within 4 weeks prior to randomization or radiation therapy within 2 weeks prior to randomization, or who has not recovered (i.e., < or = Grade 1 or at baseline) from AEs due to prior treatment
- •- Has had prior treatment with any anti-PD-1, or PD-L1, or PD-L2 agent or an antibody targeting any other immune-regulatory receptors or mechanisms. Examples of such antibodies include (but are not limited to) antibodies against IDO, PD-L1, IL-2R, and GITR
- •- Has received prior therapy with VEGF/VEGFR or mTOR targeting agents
- •- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to randomization
- •- Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic or immunosuppressive agents
- •- Has a known additional malignancy that has progressed or has required active treatment in the last 3 years
- •- Has known active CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable
- •- Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
- •- Has a clinically significant gastrointestinal (GI) abnormality including: Inability to take oral medication, Requirement for IV alimentation, Prior surgical procedures affecting absorption including total gastric resection, Treatment for active peptic ulcer within the past 6 months, Active GI bleeding, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy, Intraluminal metastatic lesion with suspected bleeding, inflammatory bowel disease, ulcerative colitis or other GI condition associated with increased risk of perforation, or history of GI perforation, Malabsorption syndromes, Inflammatory bowel disease
- •- Has QT interval corrected for heart rate (QTc) > or = 480 msec
- •- Has a history of any of the following cardiovascular conditions within 12 months of screening: Myocardial infarction, Unstable angina pectoris, Cardiac angioplasty or stenting, Coronary/peripheral artery bypass graft, Class III or IV congestive heart failure per New York Heart Association, Cerebrovascular accident or transient ischemic attack
- •- Has a history of deep vein thrombosis or pulmonary embolism within 6 months of screening
- •- Has poorly controlled hypertension defined as systolic blood pressure (SBP) > or = 150 mm Hg and/or diastolic blood pressure (DBP) > or = 90 mm Hg
- •- Has evidence of inadequate wound healing
- •- Has active bleeding disorder or other history of significant bleeding episodes within 30 days of randomization
- •- Has hemoptysis within 6 weeks prior to randomization
- •- Has current use or anticipated need for treatment with drugs or foods that are known strong cytochrome P450 (CYP3A4/5) inhibitors
- •- Has current use or anticipated need for treatment with drugs that are known strong CYP3A4/5 inducers
- •- Has had a prior solid organ transplant
研究者
相似试验
进行中（未招募）
1 期
A clinical study of Pembrolizumab plus axitinib vs. sunitinib in advanced kidney cancerAdvanced Kidney CancerMedDRA version: 20.1Level: LLTClassification code 10023400Term: Kidney cancerSystem Organ Class: 100000004864EUCTR2016-000588-17-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.840
进行中（未招募）
1 期
A clinical study of Pembrolizumab plus axitinib vs. sunitinib in advanced kidney cancerEUCTR2016-000588-17-IEMerck Sharp & Dohme LLC840
进行中（未招募）
1 期
A clinical study of Pembrolizumab plus axitinib vs. sunitinib in advanced kidney cancerAdvanced Kidney CancerMedDRA version: 19.0Level: LLTClassification code 10023400Term: Kidney cancerSystem Organ Class: 100000004864EUCTR2016-000588-17-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.840
进行中（未招募）
1 期
A clinical study of Pembrolizumab plus axitinib vs. sunitinib in advanced kidney cancerAdvanced Kidney CancerMedDRA version: 20.1Level: LLTClassification code 10023400Term: Kidney cancerSystem Organ Class: 100000004864EUCTR2016-000588-17-CZMerck Sharp & Dohme Corp.840
进行中（未招募）
1 期
A clinical study of Pembrolizumab plus axitinib vs. sunitinib in advanced kidney cancerAdvanced Kidney CancerMedDRA version: 20.1Level: LLTClassification code 10023400Term: Kidney cancerSystem Organ Class: 100000004864EUCTR2016-000588-17-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.840